SF3B1 and cancer: This indicated that inhibition of wild type SF3B1 is likely cytotoxic, also in cells lacking oncogenic SF3B1 mutations; and, since all SF3B1 mutant cancers are heterozygous, selective inhibition of mutant SF3B1 might not have strong therapeutic effects.